<DOC>
	<DOCNO>NCT02598427</DOCNO>
	<brief_summary>The purpose research study determine well pertuzumab trastuzumab work treat breast cancer spread brain . Pertuzumab trastuzumab treatment stop breast cancer cell grow abnormally inhibit ( block ) member family proteins include Human Epidermal Growth Factor Receptor 2 ( HER2 ) . Pertuzumab trastuzumab find effective HER2-positive breast cancer FDA approve treatment metastatic breast cancer outside brain give vein . This suggest pertuzumab trastuzumab may help shrink stabilize HER2-positive breast cancer spread brain research study . In research study , investigator look see whether pertuzumab trastuzumab work decrease size stabilize breast cancer spread brain .</brief_summary>
	<brief_title>Intrathecal Pertuzumab Trastuzumab Patients With New Untreated Asymptomatic Low Symptomatic Brain Metastasis HER2 Positive Breast Cancer</brief_title>
	<detailed_description>Intrathecal administration pertuzumab trastuzumab occur via lumbar puncture ( spinal tap ) fluoroscopic guidance interventional radiology Duke University Medical Center . The spinal needle insert spinal column 7 mL cerebrospinal fluid ( CSF ) collect . Once CSF remove , intrathecal pertuzumab trastuzumab administer use aseptic technique . At certain time point CSF analyze free cell DNA . If subject consent , CSF fluid also store additional future research . Patients treat use 3+3 dose-escalation design . Patients accrue next cohort ( dose escalation ) least one patient previous cohort follow six week . If dose limit toxicity ( DLT ) see patient cohort expand additional 3 patient allow 1 6 patient per cohort DLT dose escalation . Dose limit toxicity assess weekly first six week treatment . Patients treat weekly first six week every 3 week ( q21 day ) . Once maximum tolerate dose reach , additional 12 patient enrolled cohort maximum tolerate dose . The maximum number enrol patient 36 . Dosing follow : Cohort 1 - 80mg IT trastuzumab , 10mg IT pertuzumab , cohort 2 - 80mg IT trastuzumab , 20mg IT pertuzumab , cohort 3 - 80mg IT trastuzumab , 40mg IT pertuzumab , cohort 4 - 80mg IT trastuzumab , 80mg IT pertuzumab . If low dose level find toxic , trial stop without find maximum tolerate dose .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>HER2 positive 2013 ASCOCAP guideline ( IHC 3+ and/or FISH positive ; IHC 2+ HER2 patient eligible reflex FISH positive test ratio ≥ 2.0 ) breast cancer patient untreated asymptomatic minimally symptomatic brain metastasis MRI . There upper low limit size number brain metastasis . Patients previous brain metastasis completely surgically resect previously resect lesion least 1 cm target lesion ( ) study . The location previous resection cavity determine postresection MRI . Patients previous brain metastasis treat stereotactic radiosurgery ( SRS ) previously treat lesion least 1cm target lesion ( ) study . The location previous SRS treatment location determine SRS MRI . Patients steroid long dose stable ≥ 7 day No limitation prior systemic intrathecal therapy . There restriction systemic therapy enrollment . Negative serum pregnancy test premenopausal woman woman within 12 month onset menopause . Sexually active woman childbearing potential must commit 2 method contraception enrol trial continue use contraceptive least 7 month post study drug administration . Sexually active men must commit 1 method contraception enrol 7 month . Hormonal contraceptives birth control pill , patch , implant injection allow patient HR+ . Life expectancy ≥ 8 week Laboratory criterion : normal renal function : creatinine &lt; 1.5 x upper limit normal ( ULN ) ) , liver function : bilirubin ≤ 1.5 x ULN , transaminases ≤ 2 x ULN , except know hepatic disease , wherein may ≤ 5 x ULN , blood count : WBC ≥ 2.0 , Neutrophils ≥1500 , platelets ≥100,000 , Hemoglobin ≥ 10 . LVEF ( leave ventricular ejection fraction ) ≥ 50 % Karnofsky performance status ( KPS ) ≥ 50 Age ≥ 18 year Patients must ability give informed consent . Patients must sign informed consent form . No seizure , focal weakness extremity ( neurologic exam ) , stroke symptom past month . No history prior whole brain radiation . No history lumbar surgery preexist spinal condition would preclude frequent , safe , reliable lumbar puncture . No history serious cardiac arrhythmia EF &lt; 50 % . Systemic sit disease need stable systemic therapy base recent ( within 12 week ) stag scan . Radiation study allow EXCEPT localized region pain control . No history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) unless patient remission cancer therapy least 3 year . Patients significant psychiatric illness medical illness would preclude ability comply protocol . Patients may pregnant breastfeeding . No known hypersensitivity trastuzumab pertuzumab . Symptomatic intrinsic lung disease extensive tumor involvement lung result dyspnea rest .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>HER2 Positive</keyword>
	<keyword>HER2+</keyword>
	<keyword>Brain Metastases</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Intrathecal Treatment</keyword>
	<keyword>Lumbar Puncture</keyword>
	<keyword>Pertuzumab</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Duke University</keyword>
</DOC>